Quantcast

Industry news that matters to you.  Learn more

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple next-generation sequencing (NGS)-based, in vitro diagnostic (IVD) oncology tests on the Ion PGMTM Dx System.

Sequenom Collaborates With University Medical Center Hamburg-Eppendorf To Evaluate Clinical Utility Of Liquid Biopsy In Colorectal Cancer

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf (UKE) in Germany. UKE and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients. This technology has the potential to overcome the challenges and limitations associated with current methods such as imaging, colonoscopy, and invasive biopsies.

Sony DADC BioSciences and FIANOSTICS GmbH Announce Collaboration in Development of a Novel Assay Platform

In course of the Basel Life Science Week 2015 Sony DADC BioSciences and FIANOSTICS GmbH announced a collaboration on highly sensitive and rapid fluorescence immunoassays using a novel polymer/metal hybrid for the use in metal-enhanced fluorescence (MEF). Sony DADC uses its well established manufacturing processes derived from Blu-ray disc production.

Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

GATC Biotech Signs a Sales and Marketing Agreement for Products and Services With Molecular Health

GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, recently announced that it has signed a commercial agreement with Molecular Health. Under this agreement, GATC Biotech will make TreatmentMAP available to patients worldwide. The initial plans of the commercial collaboration are to market and support Molecular Health’s state-of-the-art system for tumour profiling.